Table 2.

Histamine released from the blood of S. mansoni-infected individuals, pre- and post-treatment, after in vitro stimulation with anti-IgE or schistosome Ag.

	anti-IgE		SEA		SWA
	ng/ml	%	ng/ml	%	ng/ml	%
pre-treatment (N = 32)	24.3 (20.5;38.0)	35.0 (22.6;51.8)	32.8 (23.4;44.5)	49.7 (26.9;61.6)	31.5 (23.9;44.1)	51.3 (21.5;66.9)
1-day post-treatment (N = 29)	16.5 (9.8, 26.0)	14.5 (7.5;28.5)	20.0 (9.0;36.0)	19.1 (8.0;38.1)	20.0 (9.8;31.0)	17.1 (8.2;37.8)
21-days post-treatment (N = 25)	35.5 (22.8;51.0)	20.5 (15.2;31.3)	37.5 (29.0;63.3)	25.7 (15.5;39.9)	48.0 (37.0;68.3)	33.2 (21.7;44.6)

Median histamine-release, expressed as absolute amount (ng/ml blood) or as histamine-releasability (% of total cellular histamine content of the blood) from each S. mansoni-infected individual, induced by in vitro stimulation with either anti-IgE, SEA or SWA, pre-treatment, 1-day or 21-days post-treatment. Numbers in brackets are 25% and 75% percentiles, respectively. Differences in absolute amounts between pre-treatment and either post-treatment time-points are statistically significant (p < 0.05). Differences in absolute amounts between SEA-stimulated and anti-IgE-stimulated histamine-release and between SWA-stimulated and anti-IgE-stimulated histamine-release are statistically significant (p < 0.05) at all time-points. The difference in absolute amounts between SEA-stimulated and SWA-stimulated histamine-release is statistically significant(p < 0.05) at 21-days post-treatment. Statistically significant differences in histamine-releasability are mentioned in the text. (Wilcoxon's ranks tests).